当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
2019 ASH Annual Meeting.
The Lancet Oncology ( IF 41.6 ) Pub Date : 2019-12-12 , DOI: 10.1016/s1470-2045(19)30811-3
Farhat Yaqub

David A Sallman (H Lee Moffitt Cancer Center, Tampa, FL, USA) and colleagues reported the results for the expansion cohort of the ongoing phase 1b trial of magrolimab (anti-CD47) plus azacitidine in 43 patients (median age 73 years) with untreated, intermediate to very high-risk, myelodysplastic syndrome or untreated acute myeloid leukaemia (AML). The safety profile of the drug combination, which was well tolerated, was similar to azacitidine monotherapy; treatment-related adverse events that occurred in more than 15% of patients were anaemia (37%), neutropenia (26%), and thrombocytopenia (26%). Seven (88%) of eight evaluable patients harbouring TP53 mutations—a treatment-refractory subgroup—had an objective response. Median duration response or overall survival have not been reached for patients with myelodysplastic syndrome or AML.

中文翻译:

2019 ASH年会。

David A Sallman(美国佛罗里达州坦帕市H Lee Moffitt癌症中心)和同事报告了正在进行的magrolimab(抗CD47)加azacitidine的1b期临床试验的扩增队列研究结果,该研究纳入了43位患者(中位年龄73岁),未经治疗,中度至极高风险,骨髓增生异常综合症或未经治疗的急性髓细胞性白血病(AML)。药物组合的安全性良好,耐受性良好,与阿扎胞苷单药治疗相似。超过15%的患者发生的与治疗相关的不良事件为贫血(37%),中性粒细胞减少症(26%)和血小板减少症(26%)。八名可评估的TP53患者中有七名(88%)突变(治疗难治性亚组)具有客观反应。骨髓增生异常综合症或AML患者的中位反应时间或总生存期尚未达到。
更新日期:2020-01-04
down
wechat
bug